Back to search results

Observational Study of Deucravacitinib vs. Apremilast for Plaque Psoriasis

This study is looking at how well two different medications, deucravacitinib and apremilast, work in adults with plaque psoriasis. It's an observational study, meaning researchers will watch how these drugs are used in real-world settings. You could join if you're an adult diagnosed with plaque psoriasis by a dermatologist, are starting either deucravacitinib or apremilast, and are already part of the CorEvitas Psoriasis Registry. The study will measure success by looking at changes in your body surface area (BSA), how your doctor rates your skin (Investigator Global Assessment or IGA), and how psoriasis affects your daily life (Dermatology Life Quality Index or DLQI). The current recruitment status is unclear, and the study aims to enroll 1500 participants.

Study design
This is an observational study comparing two drugs, deucravacitinib and apremilast, in adults with plaque psoriasis. It plans to enroll 1500 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for changes in body surface area at baseline and every 6 months up to 60 months or until treatment stops. Other measures will be tracked for up to 60 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05744466

A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis

Recruiting
Not specifiedAges 18+Observational
Bristol-Myers Squibb
~1,500 participants
Updated 2024-07-23 on ClinicalTrials.gov
What's tested:DeucravacitinibApremilast

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in body surface area (BSA)
Measured over At baseline and every 6 months up to 60 months or treatment discontinuation
+3 more outcomes measured

Conditions

Psoriasis

Explore related trials

Chronic small plaque psoriasis

Where it's being run

1 sites across 1 states
Massachusetts1

Study leadership

  • Bristol-Myers Squibb · STUDY_DIRECTOR · Bristol-Myers Squibb

Who to contact

BMS Study Connect Contact Center www.BMSStudyConnect.com
[email protected]
855-907-3286
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Have been diagnosed with plaque psoriasis by a dermatologist
Newly initiating an eligible medication for enrollment (i.e., deucravacitinib, apremilast)
Actively enrolled in the CorEvitas Psoriasis Registry and have documented consent to allow copies of information from the registry be used for research purposes

Exclusion

Participation (current or planned) in an interventional clinical trial (does not include observational registry or study)
Restart of treatments with the study eligible therapies previously received at any time during the participants' treatment history

What this trial measures

  • Change in body surface area (BSA)At baseline and every 6 months up to 60 months or treatment discontinuation
  • Investigator global assessment (IGA) response 0/1Up to 60 months
  • Dermatology life quality index (DLQI) response 0/1Up to 60 months
  • Time from date of treatment initiation to date of discontinuationUp to 60 months